SC
MIRM icon

Stephens Consulting’s Mirum Pharmaceuticals MIRM Stock Holding History

Stephens Consulting’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$451 – 1664
2025
Q1 		$451 Buy
+10
New +$471 ﹤0.01% 947

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stephens Consulting's MIRM Position: Q2 2025 in Review

Stephens Consulting sold out of Mirum Pharmaceuticals (MIRM) in Q2 2025, closing a stake of 10 shares — an estimated $451 sold.

Stephens Consulting first reported a position in MIRM in Q1 2025 and held it in 1 quarter. The position peaked at $451 in Q1 2025. 214 funds tracked by Wall St. Rank hold MIRM as of Q2 2025.

  • Stephens Consulting reported no remaining Mirum Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 10 Mirum Pharmaceuticals shares in Q2 2025, an estimated $451.
  • Stephens Consulting first reported a position in Mirum Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Mirum Pharmaceuticals position peaked at $451 in Q1 2025.
  • 214 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.